CN104781252B - 用作IL‑12、IL‑23和/或IFNα应答调节剂的被烷基‑酰胺取代的吡啶化合物 - Google Patents
用作IL‑12、IL‑23和/或IFNα应答调节剂的被烷基‑酰胺取代的吡啶化合物 Download PDFInfo
- Publication number
- CN104781252B CN104781252B CN201380058022.7A CN201380058022A CN104781252B CN 104781252 B CN104781252 B CN 104781252B CN 201380058022 A CN201380058022 A CN 201380058022A CN 104781252 B CN104781252 B CN 104781252B
- Authority
- CN
- China
- Prior art keywords
- substituted
- substitution
- alkyl
- compound
- occurrence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *NC(c(c(N(*)*)c1)cnc1N(*)*)=O Chemical compound *NC(c(c(N(*)*)c1)cnc1N(*)*)=O 0.000 description 19
- RKMOPXJNMQWPLH-UHFFFAOYSA-N Cc1cc(N)ncc1F Chemical compound Cc1cc(N)ncc1F RKMOPXJNMQWPLH-UHFFFAOYSA-N 0.000 description 2
- UXCIAFXCGFOUKL-UHFFFAOYSA-N NC(c(cccc1N)c1OC(F)F)=O Chemical compound NC(c(cccc1N)c1OC(F)F)=O UXCIAFXCGFOUKL-UHFFFAOYSA-N 0.000 description 2
- QXRPVDFJCFWCNO-FOVYULMLSA-N C/C(/CC=C)=N/C(/C)=N\CNc(nc1)cc(Nc(cccc2-c3nnc(C)[o]3)c2OC)c1C(NC)=O Chemical compound C/C(/CC=C)=N/C(/C)=N\CNc(nc1)cc(Nc(cccc2-c3nnc(C)[o]3)c2OC)c1C(NC)=O QXRPVDFJCFWCNO-FOVYULMLSA-N 0.000 description 1
- OPIIOZZHMCDBEM-AIGAIXFVSA-N C/C=C\C=C(/C(Nc(cc(Nc(cc1)ncc1F)nc1)c1C(NC)=O)=C)\N Chemical compound C/C=C\C=C(/C(Nc(cc(Nc(cc1)ncc1F)nc1)c1C(NC)=O)=C)\N OPIIOZZHMCDBEM-AIGAIXFVSA-N 0.000 description 1
- PQYTWWCXGBGJOZ-MJAUUJKZSA-N C/C=C\C=C(/C(S(N(C)C)(=O)=O)=C)\Nc(cc(Nc(cc1)ncc1F)nc1)c1C(NC)=O Chemical compound C/C=C\C=C(/C(S(N(C)C)(=O)=O)=C)\Nc(cc(Nc(cc1)ncc1F)nc1)c1C(NC)=O PQYTWWCXGBGJOZ-MJAUUJKZSA-N 0.000 description 1
- RDHBXUWTQCDJOS-UHFFFAOYSA-N CC(C)(C)OC(NNC(c1cccc(Nc(cc(Nc(cc2C)ncc2F)nc2)c2C(NC)=O)c1OC)=O)=O Chemical compound CC(C)(C)OC(NNC(c1cccc(Nc(cc(Nc(cc2C)ncc2F)nc2)c2C(NC)=O)c1OC)=O)=O RDHBXUWTQCDJOS-UHFFFAOYSA-N 0.000 description 1
- LPSSHFQXPDVHBR-UHFFFAOYSA-N CC(C)(C)OC(NNC(c1cccc(Nc2cc(Cl)ncc2C(NC)=O)c1OC)=O)=O Chemical compound CC(C)(C)OC(NNC(c1cccc(Nc2cc(Cl)ncc2C(NC)=O)c1OC)=O)=O LPSSHFQXPDVHBR-UHFFFAOYSA-N 0.000 description 1
- ABKZBRSWALRNAR-DMWKKASYSA-N CC(C)=N/C(/C)=N\C(Nc1ncc(C(N)=O)c(Nc2cccc(-c3ncn[n]3CC(F)(F)F)c2OC)c1)=C Chemical compound CC(C)=N/C(/C)=N\C(Nc1ncc(C(N)=O)c(Nc2cccc(-c3ncn[n]3CC(F)(F)F)c2OC)c1)=C ABKZBRSWALRNAR-DMWKKASYSA-N 0.000 description 1
- FUMZSZNYYWZHOZ-UHFFFAOYSA-N CC(CCC(C(O)=O)=C1OC)=C1Nc1cc(Cl)ncc1C(NC)=O Chemical compound CC(CCC(C(O)=O)=C1OC)=C1Nc1cc(Cl)ncc1C(NC)=O FUMZSZNYYWZHOZ-UHFFFAOYSA-N 0.000 description 1
- MODFYEFQVGSHCG-UHFFFAOYSA-N CCS(c(cccc1)c1Nc1cc(Cl)ncc1C(NC)=O)N(C)C Chemical compound CCS(c(cccc1)c1Nc1cc(Cl)ncc1C(NC)=O)N(C)C MODFYEFQVGSHCG-UHFFFAOYSA-N 0.000 description 1
- DMDAOQLUHOAYAP-UHFFFAOYSA-N CNC(c(c(Cl)c1)cnc1Cl)=O Chemical compound CNC(c(c(Cl)c1)cnc1Cl)=O DMDAOQLUHOAYAP-UHFFFAOYSA-N 0.000 description 1
- BNNFVCKPYCGBAY-UHFFFAOYSA-N CNC(c(c(Nc(cccc1-c2nnc[nH]2)c1OC)c1)cnc1Cl)=O Chemical compound CNC(c(c(Nc(cccc1-c2nnc[nH]2)c1OC)c1)cnc1Cl)=O BNNFVCKPYCGBAY-UHFFFAOYSA-N 0.000 description 1
- JPOSNUCVFKQPQP-UHFFFAOYSA-N CNC(c(c(Nc(cccc1C(N)=O)c1OC(F)F)c1)cnc1Cl)=O Chemical compound CNC(c(c(Nc(cccc1C(N)=O)c1OC(F)F)c1)cnc1Cl)=O JPOSNUCVFKQPQP-UHFFFAOYSA-N 0.000 description 1
- SHFGZSHVGYQOFV-UHFFFAOYSA-N CNC(c(c(Nc(cccc1C(N)=O)c1OC)c1)cnc1Nc(cc1)ncc1F)=O Chemical compound CNC(c(c(Nc(cccc1C(N)=O)c1OC)c1)cnc1Nc(cc1)ncc1F)=O SHFGZSHVGYQOFV-UHFFFAOYSA-N 0.000 description 1
- JCDVUCSAMRAMMH-UHFFFAOYSA-N CNC(c(c(Nc(cccc1C(O)=O)c1OC)c1)cnc1Cl)=O Chemical compound CNC(c(c(Nc(cccc1C(O)=O)c1OC)c1)cnc1Cl)=O JCDVUCSAMRAMMH-UHFFFAOYSA-N 0.000 description 1
- HTNJBWRGQLECGY-UHFFFAOYSA-N CNC(c(c(Nc1cccc(-c2c[n](C)nc2)c1OC)c1)cnc1Cl)=O Chemical compound CNC(c(c(Nc1cccc(-c2c[n](C)nc2)c1OC)c1)cnc1Cl)=O HTNJBWRGQLECGY-UHFFFAOYSA-N 0.000 description 1
- LNQAGTFFXGJKKB-UHFFFAOYSA-N CNC(c(cnc(NC(N=C1)=C=CC=C1F)c1)c1Nc1ccccc1)=O Chemical compound CNC(c(cnc(NC(N=C1)=C=CC=C1F)c1)c1Nc1ccccc1)=O LNQAGTFFXGJKKB-UHFFFAOYSA-N 0.000 description 1
- KCYCPEYNEVNMBQ-UHFFFAOYSA-N CNC(c(cnc(Nc(cc1)ncc1F)c1)c1Nc(cccc1)c1NC)=O Chemical compound CNC(c(cnc(Nc(cc1)ncc1F)c1)c1Nc(cccc1)c1NC)=O KCYCPEYNEVNMBQ-UHFFFAOYSA-N 0.000 description 1
- QDKBAXHSXOSFJD-UHFFFAOYSA-N CNC(c1cc(Nc(nc2)cc(Nc(ccc(Cl)c3)c3OC)c2C(NC)=O)ncc1)=O Chemical compound CNC(c1cc(Nc(nc2)cc(Nc(ccc(Cl)c3)c3OC)c2C(NC)=O)ncc1)=O QDKBAXHSXOSFJD-UHFFFAOYSA-N 0.000 description 1
- NIBVYEHAFBEVFI-UHFFFAOYSA-N COC(c(cccc1[N+]([O-])=O)c1O)=O Chemical compound COC(c(cccc1[N+]([O-])=O)c1O)=O NIBVYEHAFBEVFI-UHFFFAOYSA-N 0.000 description 1
- QHQBAZFSLRZYFJ-UHFFFAOYSA-N COC1OC1c(cccc1[N+]([O-])=O)c1OC Chemical compound COC1OC1c(cccc1[N+]([O-])=O)c1OC QHQBAZFSLRZYFJ-UHFFFAOYSA-N 0.000 description 1
- CMGVPTUXPJERNL-UHFFFAOYSA-N COc(c(-c1n[nH]cn1)ccc1)c1[N+]([O-])=O Chemical compound COc(c(-c1n[nH]cn1)ccc1)c1[N+]([O-])=O CMGVPTUXPJERNL-UHFFFAOYSA-N 0.000 description 1
- ZLODWCIXZJMLJL-UHFFFAOYSA-N COc(c(Br)ccc1)c1N Chemical compound COc(c(Br)ccc1)c1N ZLODWCIXZJMLJL-UHFFFAOYSA-N 0.000 description 1
- VGIYIBRECHOFLC-UHFFFAOYSA-N COc(c(C(N)=O)ccc1)c1[N+]([O-])=O Chemical compound COc(c(C(N)=O)ccc1)c1[N+]([O-])=O VGIYIBRECHOFLC-UHFFFAOYSA-N 0.000 description 1
- HCATUIMBJIDQDT-UHFFFAOYSA-N Cc1cc(C)nc(C)n1 Chemical compound Cc1cc(C)nc(C)n1 HCATUIMBJIDQDT-UHFFFAOYSA-N 0.000 description 1
- FBKLVBBVLHSFQF-UHFFFAOYSA-N Cc1cc(Nc(nc2)cc(NCc(cccc3-c4n[n](C)cn4)c3OC(F)F)c2C(NC)=O)ncc1F Chemical compound Cc1cc(Nc(nc2)cc(NCc(cccc3-c4n[n](C)cn4)c3OC(F)F)c2C(NC)=O)ncc1F FBKLVBBVLHSFQF-UHFFFAOYSA-N 0.000 description 1
- RNFXKVXFIMZVSV-UHFFFAOYSA-N Cc1cc(Nc(nc2)cc(Nc(cccc3-c4nnc[nH]4)c3OC)c2C(NC)=O)nc(C)n1 Chemical compound Cc1cc(Nc(nc2)cc(Nc(cccc3-c4nnc[nH]4)c3OC)c2C(NC)=O)nc(C)n1 RNFXKVXFIMZVSV-UHFFFAOYSA-N 0.000 description 1
- VICBYAZWSYIJBT-UHFFFAOYSA-N Cc1cc(Nc(nc2)cc(Nc(cccc3-c4nnc[o]4)c3OC)c2C(NC)=O)ncc1F Chemical compound Cc1cc(Nc(nc2)cc(Nc(cccc3-c4nnc[o]4)c3OC)c2C(NC)=O)ncc1F VICBYAZWSYIJBT-UHFFFAOYSA-N 0.000 description 1
- ICJRIGVJFWZJDN-UHFFFAOYSA-O Cc1cc(Nc2[nH+]cc(C(NC)=O)c(Nc(cccc3C(NN)=O)c3OC)c2)ncc1F Chemical compound Cc1cc(Nc2[nH+]cc(C(NC)=O)c(Nc(cccc3C(NN)=O)c3OC)c2)ncc1F ICJRIGVJFWZJDN-UHFFFAOYSA-O 0.000 description 1
- BPNMOBCFUHVNCJ-UHFFFAOYSA-N Cc1cc(Nc2ncc(C(NC)=O)c(Nc(cccc3-c4c[n](C)nc4)c3OC)c2)ncc1F Chemical compound Cc1cc(Nc2ncc(C(NC)=O)c(Nc(cccc3-c4c[n](C)nc4)c3OC)c2)ncc1F BPNMOBCFUHVNCJ-UHFFFAOYSA-N 0.000 description 1
- KESCEXHMCWQPFG-UHFFFAOYSA-N Cc1cc(Nc2ncc(C(NC)=O)c(Nc(cccc3-c4nnc[nH]4)c3OC)c2)n[n]1C Chemical compound Cc1cc(Nc2ncc(C(NC)=O)c(Nc(cccc3-c4nnc[nH]4)c3OC)c2)n[n]1C KESCEXHMCWQPFG-UHFFFAOYSA-N 0.000 description 1
- QLYXCLHGLZXVRL-UHFFFAOYSA-N Cc1cc(Nc2ncc(C(NC)=O)c(Nc3cccc(C(O)=O)c3OC)c2)ncc1F Chemical compound Cc1cc(Nc2ncc(C(NC)=O)c(Nc3cccc(C(O)=O)c3OC)c2)ncc1F QLYXCLHGLZXVRL-UHFFFAOYSA-N 0.000 description 1
- QERLQNIZXCNCDT-UHFFFAOYSA-N Cc1nc(-c2cccc(Nc3cc(Nc4nc(C)nc(C)c4)ncc3C(NC)=O)c2OC)n[n]1CC(F)F Chemical compound Cc1nc(-c2cccc(Nc3cc(Nc4nc(C)nc(C)c4)ncc3C(NC)=O)c2OC)n[n]1CC(F)F QERLQNIZXCNCDT-UHFFFAOYSA-N 0.000 description 1
- PCBKIUOQTRMLJO-UHFFFAOYSA-N Cc1nnc(-c2cccc(Nc(cc(Nc3nc(C)nc(C)c3)nc3)c3C(NC)=O)c2OC)[nH]1 Chemical compound Cc1nnc(-c2cccc(Nc(cc(Nc3nc(C)nc(C)c3)nc3)c3C(NC)=O)c2OC)[nH]1 PCBKIUOQTRMLJO-UHFFFAOYSA-N 0.000 description 1
- YJTXQLYMECWULH-UHFFFAOYSA-N Nc(cc1)ncc1F Chemical compound Nc(cc1)ncc1F YJTXQLYMECWULH-UHFFFAOYSA-N 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Nc1ccccc1 Chemical compound Nc1ccccc1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Dermatology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261723854P | 2012-11-08 | 2012-11-08 | |
| US61/723854 | 2012-11-08 | ||
| PCT/US2013/068842 WO2014074660A1 (en) | 2012-11-08 | 2013-11-07 | ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNα RESPONSES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104781252A CN104781252A (zh) | 2015-07-15 |
| CN104781252B true CN104781252B (zh) | 2017-11-17 |
Family
ID=49667568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380058022.7A Active CN104781252B (zh) | 2012-11-08 | 2013-11-07 | 用作IL‑12、IL‑23和/或IFNα应答调节剂的被烷基‑酰胺取代的吡啶化合物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9315494B2 (enExample) |
| EP (1) | EP2922841B8 (enExample) |
| JP (1) | JP6259463B2 (enExample) |
| KR (1) | KR102233252B1 (enExample) |
| CN (1) | CN104781252B (enExample) |
| AR (1) | AR093403A1 (enExample) |
| AU (1) | AU2013341185B2 (enExample) |
| BR (1) | BR112015010244A8 (enExample) |
| CA (1) | CA2890929A1 (enExample) |
| EA (1) | EA028526B1 (enExample) |
| IL (1) | IL238554A0 (enExample) |
| MX (1) | MX2015005272A (enExample) |
| SG (1) | SG11201503396UA (enExample) |
| TW (1) | TWI620737B (enExample) |
| WO (1) | WO2014074660A1 (enExample) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104903301B (zh) | 2012-11-08 | 2017-08-29 | 百时美施贵宝公司 | 可用于调节IL‑12、IL‑23和/或IFNα的烷基酰胺取代的嘧啶化合物 |
| RS58187B1 (sr) | 2012-11-08 | 2019-03-29 | Bristol Myers Squibb Co | Amidom-supstituisana heterociklična jedinjenja korisna kao modulatori il-12, il-23 i/ili ifn-alfa |
| SG11201503397YA (en) | 2012-11-08 | 2015-05-28 | Bristol Myers Squibb Co | Heteroaryl substituted pyridyl compounds useful as kinase modulators |
| TWI582077B (zh) | 2013-11-07 | 2017-05-11 | 必治妥美雅史谷比公司 | 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物 |
| EP3080131B1 (en) | 2013-12-10 | 2018-10-10 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses |
| TW201609693A (zh) | 2014-01-03 | 2016-03-16 | 必治妥美雅史谷比公司 | 雜芳基取代之菸鹼醯胺化合物 |
| WO2016001341A1 (en) * | 2014-07-03 | 2016-01-07 | F. Hoffmann-La Roche Ag | Sulfonylaminopyridine compounds, compositions and methods of use |
| WO2016022626A1 (en) * | 2014-08-06 | 2016-02-11 | Merck Sharp & Dohme Corp. | Heterocyclic cgrp receptor antagonists |
| CN109641906B (zh) | 2015-06-24 | 2021-10-01 | 百时美施贵宝公司 | 杂芳基取代的氨基吡啶化合物 |
| CN107849039B (zh) | 2015-06-24 | 2020-07-03 | 百时美施贵宝公司 | 经杂芳基取代的氨基吡啶化合物 |
| AR105114A1 (es) | 2015-06-24 | 2017-09-06 | Bristol Myers Squibb Co | Compuestos de aminopiridina sustituida con heteroarilo |
| EA035899B1 (ru) * | 2015-11-26 | 2020-08-28 | Новартис Аг | Производные диаминопиридина в качестве ингибиторов jak |
| EP3848370B1 (en) | 2016-10-14 | 2025-05-07 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors and uses thereof |
| IL266109B2 (en) | 2016-10-21 | 2025-05-01 | Nimbus Lakshmi Inc | Tyk2 inhibitors and uses thereof |
| JP7046092B2 (ja) * | 2016-12-13 | 2022-04-01 | ブリストル－マイヤーズ スクイブ カンパニー | Ｉｌ－１２、ｉｌ－２３および／またはｉｆｎアルファ応答の調節剤としてのホスフィンオキシドアルキルアミド置換ヘテロアリール化合物 |
| IL269036B2 (en) | 2017-03-08 | 2023-03-01 | Nimbus Lakshmi Inc | tyk2 inhibitors, uses and methods for their production |
| HRP20211583T1 (hr) | 2017-05-11 | 2022-01-07 | Bristol-Myers Squibb Company | Tienopiridini i benzotiofeni korisni kao irak4 inhibitori |
| TWI776810B (zh) * | 2017-05-12 | 2022-09-11 | 瑞士商諾華公司 | 新穎二胺基吡啶衍生物 |
| EP3658557B1 (en) | 2017-07-28 | 2024-06-05 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors and uses thereof |
| KR102702228B1 (ko) * | 2017-11-21 | 2024-09-02 | 브리스톨-마이어스 스큅 컴퍼니 | 술폰 피리딘 알킬 아미드-치환된 헤테로아릴 화합물 |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2019160875A1 (en) | 2018-02-13 | 2019-08-22 | Rutgers, The State University Of New Jersey | Antibacterial agents: soluble salts and aqueous formulations of pyronins |
| EP3752143B1 (en) | 2018-02-13 | 2025-04-09 | Rutgers, The State University of New Jersey | Antibacterial agents: o-alkyl-deuterated pyronins |
| WO2019173507A1 (en) | 2018-03-06 | 2019-09-12 | Rutgers, The State University Of New Jersey | Antibacterial agents : arylalkylcarboxamido phloroglucinols |
| TW201940483A (zh) | 2018-03-12 | 2019-10-16 | 美商艾伯維有限公司 | 酪胺酸激酶２介導的傳訊之抑制劑 |
| EP3768667B1 (en) * | 2018-03-22 | 2023-04-12 | Bristol-Myers Squibb Company | Heterocyclic compounds comprising pyridine useful as modulators of il-12, il-23 and/or ifn alpha responses |
| WO2020010227A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| WO2020081508A1 (en) | 2018-10-15 | 2020-04-23 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| EA202191142A1 (ru) * | 2018-10-30 | 2021-07-20 | Бристол-Маерс Сквибб Компани | Амидзамещенные гетероциклические соединения |
| US11352350B2 (en) | 2018-11-30 | 2022-06-07 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| WO2020112937A1 (en) | 2018-11-30 | 2020-06-04 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| AU2020212001A1 (en) | 2019-01-23 | 2021-07-22 | Takeda Pharmaceutical Company Limited | TYK2 inhibitors and uses thereof |
| JP7652697B2 (ja) * | 2019-01-28 | 2025-03-27 | 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 | ピリダジン系誘導体阻害剤、その製造方法及び使用 |
| CN114423757B (zh) | 2019-07-18 | 2024-07-02 | 百时美施贵宝公司 | 可用作irak4抑制剂的三环杂芳基化合物 |
| WO2021011727A1 (en) | 2019-07-18 | 2021-01-21 | Bristol-Myers Squibb Company | PYRAZOLO[3,4-d]PYRROLO[1,2-b]PYRIDAZINYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS |
| KR20220041124A (ko) | 2019-07-23 | 2022-03-31 | 브리스톨-마이어스 스큅 컴퍼니 | Irak4 억제제로서 유용한 티에노피리디닐 및 티아졸로피리디닐 화합물 |
| CN114174279B (zh) | 2019-08-06 | 2024-07-02 | 百时美施贵宝公司 | 可用作irak4抑制剂的双环杂环化合物 |
| US12215105B2 (en) | 2019-09-13 | 2025-02-04 | Nimbus Saturn, Inc. | HPK1 antagonists and uses thereof |
| US12421230B2 (en) | 2020-02-03 | 2025-09-23 | Bristol-Myers Squibb Company | Tricyclic heteroaryl compounds useful as IRAK4 inhibitors |
| WO2021158495A1 (en) | 2020-02-03 | 2021-08-12 | Bristol-Myers Squibb Company | Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as irak4 inhibitors |
| US20220330549A1 (en) * | 2020-03-11 | 2022-10-20 | Northwest A&F University | Use of n-benzylbenzamide-based compound as herbicide |
| KR20230004612A (ko) * | 2020-04-14 | 2023-01-06 | 고사머 바이오 서비시즈 인코포레이티드 | 염증성 질병의 치료를 위한 치환된 피리딘 |
| EP4143180A1 (en) * | 2020-04-28 | 2023-03-08 | Bristol-Myers Squibb Company | Substituted n-(methyl-d3)pyridazine-3-carboxamide or n-(methyl-d3)-nicotinamide compounds as il-12, il-23 and/or ifnalpha modulators |
| CN115843296B (zh) * | 2020-08-07 | 2024-03-08 | 南京迈晟科技有限责任公司 | Cdk9抑制剂及其用途 |
| CN114181257B (zh) * | 2020-09-14 | 2025-02-14 | 四川科伦博泰生物医药股份有限公司 | 吡啶类化合物，包含其的药物组合物，其制备方法及其用途 |
| EP4232425A4 (en) | 2020-10-23 | 2024-07-24 | Nimbus Clotho, Inc. | Ctps1 inhibitors and uses thereof |
| EP4263523A2 (en) * | 2020-12-16 | 2023-10-25 | IFM Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| TW202241891A (zh) | 2020-12-30 | 2022-11-01 | 美商凱麥拉醫療公司 | Irak降解劑及其用途 |
| KR20230152692A (ko) | 2021-02-02 | 2023-11-03 | 리미널 바이오사이언시스 리미티드 | Gpr84 길항제 및 이의 용도 |
| EP4288427A1 (en) | 2021-02-02 | 2023-12-13 | Liminal Biosciences Limited | Gpr84 antagonists and uses thereof |
| US12252488B2 (en) | 2021-02-12 | 2025-03-18 | Nimbus Saturn, Inc. | HPK1 antagonists and uses thereof |
| JP2024506656A (ja) | 2021-02-15 | 2024-02-14 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ４分解剤およびその使用 |
| JP2024508794A (ja) * | 2021-02-19 | 2024-02-28 | スドー バイオサイエンシーズ リミテッド | Ｔｙｋ２阻害剤およびその使用 |
| WO2022175746A1 (en) * | 2021-02-19 | 2022-08-25 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| EP4294808A1 (en) * | 2021-02-19 | 2023-12-27 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| WO2022175745A1 (en) * | 2021-02-19 | 2022-08-25 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| WO2022187856A1 (en) | 2021-03-05 | 2022-09-09 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
| US12071442B2 (en) | 2021-03-29 | 2024-08-27 | Nimbus Saturn, Inc. | Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists |
| WO2022217276A1 (en) | 2021-04-09 | 2022-10-13 | Nimbus Clio, Inc. | Cbl-b modulators and uses thereof |
| IL312330A (en) | 2021-10-25 | 2024-06-01 | Kymera Therapeutics Inc | Tyk2 degraders and uses thereof |
| WO2023076556A1 (en) | 2021-10-29 | 2023-05-04 | Kymera Therapeutics, Inc. | Irak4 degraders and synthesis thereof |
| JP2025503448A (ja) * | 2021-12-16 | 2025-02-04 | リンク ファーマシューティカルズ シーオー．エルティーディー． | Ｔｙｋ２阻害剤および組成物ならびにその方法 |
| WO2023108536A1 (en) * | 2021-12-16 | 2023-06-22 | Lynk Pharmaceuticals Co. Ltd. | Tyk2 inhibitors and compositions and methods thereof |
| JP2025504059A (ja) | 2022-01-31 | 2025-02-06 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋデグレーダー及びその使用 |
| CN116693449A (zh) | 2022-03-04 | 2023-09-05 | 上海致根医药科技有限公司 | 用作tyk2抑制剂的化合物、其制备方法及其在医药上的应用 |
| US20250270190A1 (en) * | 2022-04-19 | 2025-08-28 | Blueprint Medicines Corporation | Kit inhibitors |
| WO2023227946A1 (en) * | 2022-05-27 | 2023-11-30 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| WO2024028364A1 (en) | 2022-08-02 | 2024-02-08 | Liminal Biosciences Limited | Aryl-triazolyl and related gpr84 antagonists and uses thereof |
| JP2025527248A (ja) | 2022-08-02 | 2025-08-20 | リミナル・バイオサイエンシーズ・リミテッド | 置換ピリドンｇｐｒ８４アンタゴニスト及びその使用 |
| EP4565568A1 (en) | 2022-08-02 | 2025-06-11 | Liminal Biosciences Limited | Heteroaryl carboxamide and related gpr84 antagonists and uses thereof |
| WO2024249855A1 (en) * | 2023-06-02 | 2024-12-05 | Idrx, Inc. | Combination therapy comprising kit inhibitors for use in the treatment of cancer |
| TW202529769A (zh) | 2023-09-21 | 2025-08-01 | 日商武田藥品工業股份有限公司 | Ｔｙｋ２抑制劑及其用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7176214B2 (en) | 2003-05-21 | 2007-02-13 | Bristol-Myers Squibb Company | Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same |
| GB0719644D0 (en) * | 2007-10-05 | 2007-11-14 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| JPWO2010058846A1 (ja) * | 2008-11-21 | 2012-04-19 | アステラス製薬株式会社 | ４，６−ジアミノニコチンアミド化合物 |
| WO2012062704A1 (en) * | 2010-11-09 | 2012-05-18 | Cellzome Limited | Pyridine compounds and aza analogues thereof as tyk2 inhibitors |
-
2013
- 2013-11-07 AU AU2013341185A patent/AU2013341185B2/en not_active Ceased
- 2013-11-07 MX MX2015005272A patent/MX2015005272A/es unknown
- 2013-11-07 TW TW102140570A patent/TWI620737B/zh not_active IP Right Cessation
- 2013-11-07 KR KR1020157014693A patent/KR102233252B1/ko active Active
- 2013-11-07 CA CA2890929A patent/CA2890929A1/en not_active Abandoned
- 2013-11-07 SG SG11201503396UA patent/SG11201503396UA/en unknown
- 2013-11-07 JP JP2015541882A patent/JP6259463B2/ja active Active
- 2013-11-07 EP EP13795911.0A patent/EP2922841B8/en active Active
- 2013-11-07 WO PCT/US2013/068842 patent/WO2014074660A1/en not_active Ceased
- 2013-11-07 EA EA201590913A patent/EA028526B1/ru not_active IP Right Cessation
- 2013-11-07 US US14/441,193 patent/US9315494B2/en active Active
- 2013-11-07 BR BR112015010244A patent/BR112015010244A8/pt not_active Application Discontinuation
- 2013-11-07 AR ARP130104094A patent/AR093403A1/es unknown
- 2013-11-07 CN CN201380058022.7A patent/CN104781252B/zh active Active
-
2015
- 2015-04-30 IL IL238554A patent/IL238554A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR093403A1 (es) | 2015-06-03 |
| JP6259463B2 (ja) | 2018-01-10 |
| US20150307483A1 (en) | 2015-10-29 |
| TWI620737B (zh) | 2018-04-11 |
| CA2890929A1 (en) | 2014-05-15 |
| KR20150081338A (ko) | 2015-07-13 |
| US9315494B2 (en) | 2016-04-19 |
| CN104781252A (zh) | 2015-07-15 |
| MX2015005272A (es) | 2015-07-14 |
| EA028526B1 (ru) | 2017-11-30 |
| SG11201503396UA (en) | 2015-05-28 |
| WO2014074660A1 (en) | 2014-05-15 |
| IL238554A0 (en) | 2015-06-30 |
| TW201422587A (zh) | 2014-06-16 |
| AU2013341185A1 (en) | 2015-07-02 |
| AU2013341185B2 (en) | 2017-07-13 |
| EP2922841B1 (en) | 2017-06-07 |
| BR112015010244A8 (pt) | 2019-10-01 |
| EP2922841B8 (en) | 2017-08-02 |
| BR112015010244A2 (pt) | 2017-07-11 |
| JP2016506368A (ja) | 2016-03-03 |
| KR102233252B1 (ko) | 2021-03-26 |
| EA201590913A1 (ru) | 2015-10-30 |
| EP2922841A1 (en) | 2015-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104781252B (zh) | 用作IL‑12、IL‑23和/或IFNα应答调节剂的被烷基‑酰胺取代的吡啶化合物 | |
| CN106660960B (zh) | 用作IL-12、IL-23和/或IFNα响应的调节剂的烷基-酰胺-取代的吡啶化合物 | |
| US11021475B2 (en) | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | |
| CN108473500A (zh) | 用作IL-12、IL-23和/或IFNα响应的调节剂的咪唑并哒嗪化合物 | |
| CN110191887B (zh) | IL-12、IL-23和/或IFN-α的咪唑并哒嗪调节剂 | |
| HK1226400B (en) | Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifnalpha responses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |